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excellent phariiiacokinetic and pharniacodynaniic characteristics that 
ensure its clinical efficacy 
Role of quinolones in acute exacerbations of 
chronic bronchitis 
J. Lorenz. Krt-iskrankriikans Liidensrkeid, h e r e  .4ht. 11, Liidenschrid, 
Germany 
Chronic bronchitis (CB) is one of the most prevalent chronic diseases 
in adults. In general, it is a progressive disorder characterized by acute 
emccrbations (AECB). The role of antibiotics in the management of  
AECB has been under dispute. However, several good clinical studies 
have shown advantages of antibiotic therapy. Hacmopltilns i+enzae 
and pneuiiiococci are the most prevalent pathogens in the sputum of 
patients with AECB, though enterobacteria, Aforaxelh mtarrkalis and 
Cklamydia piienmowiac have been isolated in a proportion of cases. 
During the coune of CB, the likelihood of developing purulent 
AECB increases, and the prevalence of enterobacteria, or even 
Psrudomorzas acrusqinosa infection, increases. Therefore, antibacterial 
treatnient in patients with advanced disease should cover Gram- 
negative bacteria. Older yuinolones, such as ciprofloxacin and 
ofloxacin, have limited use in AECB due to their poor activity against 
Gram-positive bacteria. Recently, extended-spectrum compounds, 
such as ti-ovafloxacin, have been developed. Trovafloxaciri has been 
compared in clinical trials with standard antibiotic agents, such as 
three-times-daily anioxycillin, alone or in combination with 
clavulanic acid, in patients with Aiithonisen class 1 (severe) AECB. 
At a dose of 100 or 200 tng once daily, it has been shown to have 
comparable c1inic.d efficacy and safety to the comparator agents, with 
bettcr eradication of some key pathogens at the 700-iiig dose. The  
antibacterial spectruiii and clinical eficacy of trovafloxacin and other 
compounds has led to the inclusion of the newer yuinolones in new 
European guidelines for the standard treatment of AECB. Trova- 
floxacin is especially appropriate in the treatment of high-risk patients 
with advanced disease. 
Empirical treatment of community-acquired 
pneumonia 
J. Garau. Hmpiral Mirtna dc X w a s s a ,  Dept qf Alrdicine, Barrcloria, 
Spaiii 
Early identification of the causative organisms in conimunity- 
acquired pneumonia (CAP) is rare; antimicrobial therapy tends, 
therefore, to be empirical. The pathogens most frequently associated 
with CAP include: Strrptororcus pnnrmoriiae, Hacmoplzilus influcn:ae 
and Aloraxrlla catarrkalis. However, atypical pathogens, such as 
Le,qionr/la prirumophiia, Cklamydio pnertruoniar and .%lyroplasnza 
pricwnoriiac, also have an important role in the etiology of the disease. 
T h u ,  any antimicrobial agent chosen should ideally have a broad 
spectrum of activity. Penicillins and other beta-lactams are corninonly 
prescribed to treat CAP. There are, however, limitations to their use. 
First, changes have occurred in antibacterial susceptibility patterns 
over the last 10-1 5 yrars. Peiiicillin-re.;istant strains of pneuniococci 
have been reported in all areas of the world. Second, beta-lactamase 
production is increasing among strains of H.  it$ueir;ac and, in 
particular, IZI. catarrkalis. Also, beta-lactams are inactive against 
atypical pathogens; thus, agents such as the iiiacrolides are increas- 
ingly being used. Other agents have therefore been investigated for 
use as enipirical therapy of CAP. Fluoroquinolones have been used 
against respiratory infections with some succe~s. Their use has, 
however, been limited by lack of activity of the older quinolones 
against pneumococci. However, the new-generation fluoro- 
yuinolones, such 3s trovafloxacin and others, are highly actlve agaimt 
pneuiiiococci (including penicillin-resistant strains) ;tiid atypical 
pathogens, while retaining activity against Graiii-negative pathogens. 
Clinical trials have confirmed their efic'icy in the treatnient of CAI', 
and suggest that they are an approprlate alternative choice for 
empirical therapy. 
(s2181 Achieving early hospital discharge with 
community-acquired pneumonia 
M.S. Niederiiim. Divisroii qf Pulmonary arid Critiral C u r  ,\frdicirie, 
L+'itit/irop- Lrnitmiry Hospital, hliticoln, XI; 
In trying to achieve early discharge of pdtients with CAP, we need 
to focus on (1) appropriate hospital admission only for those patients 
who can most benefit; (2)  timely use of the most etrective therapy; 
and (3) early switch to o rd  therapy. Defined risk factors for mortality 
in CAP can be incorporated into a prognostic rule to stratify patients 
and help guide the admission decision. As many as 40"% of liospitaliz- 
ations could be eliminated by using such a rule, although this 
approach riiay lead to some non-admitted patients dying or sub- 
sequently requiring ICU admission. An alternative is to me prog- 
nostication rules (e.g. the British Thoracic Society rule) only to help 
clinicians identify severely ill patients. Optimal therapy of CAP 
requires rapid administration of an effective antibiotic regimen. Data 
show that initial therapy reduces mortality if given within X h of 
admission, and that a B-lactani/macrolide combination leads to a 
lower mortality rate than other regimens. Following a good response 
to initial therapy, 3 \witch to oral agents is necessary, and can typically 
be done by day 3 of hospitalization,. The patient can then be promptly 
discharged, as no benefit s eem to come with observation of oral 
therapy in the hospital. Done routinrly, this may actually reduce 
mortality. New fluoroyuinolones, such as trovafloxacin. i m y  .idd to 
a inore efficient ute of hospital resources in  CAI', due to their broad 
spectruin of activity, once-daily dosing, and high oral bioavailability. 
Trovafloxacin 200 nig O D  has been \howl1 to be a\ effiective as 
standard agents in clinicai studies of hospitalized patients with CAt: 
and has facilitated an early switch to ord therapy. 
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Several unique hantaviruses hme bren discovered in Eur.isia in recent 
years. Tula (TUL) virus was first detected in hfirrotus arialis and ,Zf. 
rossiacnirridionalis trapped in western Russia and later al\o found in 
Slovakia, the Czech Republic, Austria, Poland and Switzerland. 
Khabarovsk (KBR) virus was detected in ,%I. jwfis trapped in Far- 
Eastern Russia. Topografov (TOP) virus, carried by L e m m n ~  sihiricus, 
has been detected in animals trapped in Siberia. The phylogenetic 
relationships of KBK, TOP and I'numala (PUU) hantaviruses and 
their respective carrier rodents suggest that an exceptional host- 
switch has taken place during the evolution of these viruses. 
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The high and sometimes most complex serologic cross-reactivity 
among the hantaviruses has complicated the investigations con- 
cerning potential human infections and diseases caused by the 
newly discovered viruses and has sometimes also made old sero- 
epidemiologic data uncertain. Recent analyses by neutralization assay 
and direct RT-PCR have proven Dobrava (DOB) virus as the agent 
of severe HFRS in Bosnia-Herzegovina, Greece, Albania, Slovenia 
and Germany Moreover, DOB has been shown to cause human 
infections also in north-eastern Europe, e.g. in Estonia and western 
Russia. These findings have major implications for the interpretation 
of serologic data and for future vaccine strategies. 
Hemorrhagic fever with renal syndrome 
(HFRS): clinics, treatment, and prophylaxis 
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Clinically important strains of hantaviruses of the Old World (OW- 
HTV) isolated so far are Hantaan (HTN, 1977), Seoul (SEO, 1982). 
Puumala (PUU, 1983). and Dobrava (DOB, 1988). PUU is the 
etiologic agent of nephropathia epidemica (NE), spread by red bank 
voles throughout Russia and northwest Europe. In contrast to New 
World HTV, which primarily affect the lung, OW-HTV induce 
variable degrees of (transient) proteinuria and acute renal failure 
(ARF); hence the W H O  denomination of hemorrhagic fever with 
renal syndrome (HFRS). However, internal hemorrhages are present 
in only 25% of HTN or DOB cases, and ARF can be absent or 
minimal. Exceptional complications in H T N  are hemorrhagic 
necrosis of the pituitary and/or adrenal glands, and can consist in 
PUU of acute pulmonary edema, pericarditis, acalculous chole- 
cystitis, encephalitis, and Guillain-BarrC syndrome. We noted acute 
myopia with blurred vision, conjunctival suffusion, chemosis, 
diplopia, uni- or bilateral acute glaucoma, retinal bleeding, and even 
transient blindness in up to 25% of PUU cases. 
Initial laboratory anomalies common to most HTV infections, and 
indicative of clinical severity, are (transient) thmnibocytopenia, and 
strikingly low serutn cholesterol, combined with high triglyceride 
levels. Since cytopathic effects are conspicuously lacking, 
imniunopathologic mechanisms, determined by host factors, and 
capillary leakage in target organs are presumably the key factors in 
pathogenesis. Treatment is supportive, but can include dialysis and/or 
ventilation. So far, the only current prophylaxis consists of reduced 
exposure to aerosolized rodent excreta. 
Pathogenesis of hantavirus infections 
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Hantavirus infections are asymptomatic in their adult carrier rodents, 
but cause in humans hemorrhagic fever with renal syndrome (HFRS) 
and hantavirus pulmonary syndrome, both with significant mortality. 
/3? integrins mediate entry of pathogenic hantaviruses. In cell culture, 
hantaviruses do not cause cytopathic effects. The mechanisms of 
disease are not well understood. Cytotoxic T-cells have been demon- 
strated but their role is not clear. Increased capillary permeability is 
central in the pathogenesis of hantavirus infections. Inflammatory 
mediators of the host immune response presumably play a significant 
role in the capillary leak that may result in abrupt hypotension and 
shock. Mediators released by activated macrophages, including NO 
and TNF-alpha, are considered important. One of our aiins is to 
define the molecular determinants of hantavirus pathogenicity and to 
learn why the outcome of hantavirus-human interaction varies 
between individuals. It seems that both the genetic characteristics of 
the virus and the genetic susceptibility of patients contribute to this 
variability. In the carrier rodents, hantaviruses are composed of a 
genetic swarm of quasi-species. Adaptation from rodents to primate 
cells is selective and leads to defined genetic changes. 
There is suggestive evidence that natural reassortant hantaviruses 
are involved in human infection. We have linked the severity of 
Puumala hantavirus infection (nephropathia epidemica, NE) to 
certain host genes. HLA alleles B8 DR3 and DQ2 are strongly 
associated with severe NE and with hantavirus PCR positivity, HLA 
B27 is associated with mild NE, and the high-producer allele of 
TNF-alpha is a part of the susceptibility M H C  haplotype in severe 
NE . 
Infectious disease in the 21st century 
(52271 Advances in influenza management: focus on 
neuraminidase inhibitors and intranasal 
vaccine 
E Hayden. L7niversity .f I'itginia School ofhledicine, Charlottesvilk, 
1:4, USA 
Influenza viruses are prototypic re-emergent pathogens that represent 
continuing threats to human health. Influenza neuraminidase plays 
an essential role in replication by allowing release of virus from 
infected cells and facilitating spread within the respiratory tract. The 
active enzyme site is highly conserved across influenza A and B 
viruses. Zanamivir (GGI 67) and GS4071 are potent, selective 
influenza neuraininidase inhibitors in vitro but have different 
pharmacokinetic properties. Both topical zanamivir and oral 
GS4104, the ethyl 'ester prodrug of (34071, are active in experi- 
mental animal and human infections. Phase I11 studies have 
confirmed that twice-daily inhaled zanamivir treatment ameliorates 
symptoms and, in high-risk persons, reduces complications. A 4- 
week prophylaxis study found 67% protection against influenza illness 
in ambulatory adults. Phase I11 trials of oral GS4104 have found that 
twice-daily dosing is effective in treating acute influenza in adults and 
also reduces the risk of complications by about one-half. Once-daily 
dosing was 82% effective in preventing influenza illness. Studies of 
these drugs for prevention of influenza in nursing homes, and for 
treatment of influenza in high-risk patients and children, and of 
nebulized zanamivir for treating serious influenza in hospitalized 
patients, are in progress. Intranasal delivery of trivalent, cold-adapted, 
live-attenuated influenza vaccine is highly protective in young 
children. Protection was shown last season against the A/Sydney drift 
variant, for which the injected vaccine provided minimal protection, 
and also in working adults. In summary, neuraminidase inhibitors and 
the intranasal cold-adapted vaccine provide new means of confront- 
ing the continuing threat of influenza infections. 
